No Data
No Data
Here's Why Fujian Wanchen Biotechnology Group (SZSE:300972) Has A Meaningful Debt Burden
Fujian Wanchen Biotechnology Group: Fujian Wanchen Biotechnology Group Co., Ltd.'s performance forecast for the first half of 2024.
Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Subdued P/S Might Signal An Opportunity
Be Wary Of Fujian Wanchen Biotechnology Group (SZSE:300972) And Its Returns On Capital
Snack discount leader's profit inflection point has arrived | Insight Research
Wanchen Group's net profit for the third quarter was positive, and the net interest rate increased for four consecutive quarters.
Wanchen Group (300972.SZ) announced first-quarter results, net profit of 6.2382 million yuan, a decrease of 88.15%
According to the Zhitong Finance App, Wanchen Group (300972.SZ) released its report for the first quarter of 2024. The company's revenue was 4.83 billion yuan, an increase of 534.03% over the previous year. Net profit attributable to shareholders of listed companies was 6.2382 million yuan, a year-on-year decrease of 88.15%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.98,800 yuan, a year-on-year decrease of 96.17%. Basic earnings per share were $0.0388.
No Data